top of page



  1. International Agency forResearchonCancer. GLOBOCAN 2018: estimatedcancerincidence, mortality and prevalenceworldwide in 2018.Disponible en

  2. Shanbhag S, Ambinder RF. Hodgkinlymphoma: A review and updateonrecentprogress. CA Cancer J Clin. 2018;68(2):116-132.

  3. Townsend W, Linch D. Hodgkin'slymphoma in adults. Lancet. 2012;380(9844):836-47.

  4. Kallerman R, Bope, Edward T. Conn’s current therapy. Philadelphia, PA: Elsevier, 2018

  5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendationsforinitialevaluation, staging, and response assessment of Hodgkin and non-Hodgkinlymphoma: the Lugano classification. J ClinOncol. 2014;32(27):3059-68.

  6. Gunderson, Leonard L., Joel E. Tepper, and Jeffrey A. Bogart. Clinical radiation oncology. Philadelphia, PA: Elsevier, 2016.

  7. Illidge T, Specht L, Yahalom J, et al. Modern radiationtherapyfor nodal non-Hodgkinlymphoma-target definition and doseguidelinesfromthe International LymphomaRadiationOncologyGroup. Int J RadiatOncolBiolPhys. 2014;89(1):49-58.

  8. Specht L, Yahalom J, Illidge T, et al. Modern radiationtherapyforHodgkinlymphoma: field and doseguidelinesfromtheinternationallymphomaradiationoncologygroup (ILROG). Int J RadiatOncolBiolPhys. 2014;89(4):854-62.

  9. Andrea K. RadiationTherapy in Lymphoma Revisado por última vez 30 Abr 2018

  10. Tilly H, Gomes da silva M, Vitolo U, et al. Diffuselarge B-celllymphoma (DLBCL): ESMO ClinicalPracticeGuidelinesfor diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v116-25.

  11. Bröckelmann PJ, Sasse S, Engert A. Balancingrisk and benefit in early-stageclassicalHodgkinlymphoma. Blood. 2018;131(15):1666-1678.

  12. Bonadonna G, Bonfante V, Viviani S, Di russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-fieldradiotherapy in early-stageHodgkin'sdisease: long-termresults. J ClinOncol. 2004;22(14):2835-41.

  13. Engert A, Schiller P, Josting A, et al. Involved-fieldradiotherapyisequallyeffective and lesstoxiccomparedwith extended-fieldradiotherapyafterfourcycles of chemotherapy in patientswithearly-stageunfavorableHodgkin'slymphoma: results of the HD8 trial of the German Hodgkin'sLymphomaStudyGroup. J ClinOncol. 2003;21(19):3601-8.

  14. Eich, H.T. &Kriz, Jan&Klimm, B &Sasse, Stephanie &Görgen, H &Diehl, Volker&Borchmann, P & P Mueller, R &Engert, A. (2012). Involved-field (IF) Versus Extended-field (EF) RadiationTherapy (RT) forPatients in EarlyUnfavorableStages of HodgkinLymphoma: 10-year Update of the HD8 Trial of the German HodgkinStudyGroup (GHSG). International Journal of RadiationOncology*Biology*Physics. 84. S70.

  15. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-fieldradiation in early-stageHodgkin'sdisease. N Engl J Med. 2007;357(19):1916-27.

  16. Engert A, Franklin J, Eich HT, et al. Twocycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-fieldradiotherapyis superior to radiotherapyalone in early favorable Hodgkin'slymphoma: final results of the GHSG HD7 trial. J ClinOncol. 2007;25(23):3495-502.

  17. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-basedtherapy in limited-stageHodgkin'slymphoma. N Engl J Med. 2012;366(5):399-408.

  18. E. M. Noordijk, J. Thomas, C. Fermé, M. B. van ’t Veer et al. Firstresults of the EORTC-GELA H9 randomizedtrials: the H9-F trial (comparing 3 radiationdoselevels) and H9-U trial (comparing 3 chemotherapyschemes) in patientswith favorable orunfavorableearlystageHodgkin’slymphoma (HL). Journal of ClinicalOncology 2005 23:16_suppl, 6505-6505. 

  19. Blank O, Von tresckow B, Monsef I, Specht L, Engert A, Skoetz N. Chemotherapyalone versus chemotherapy plus radiotherapyforadultswithearlystageHodgkinlymphoma. Cochrane DatabaseSyst Rev. 2017;4:CD007110.

  20. Engert A, Plütschow A, Eich HT, et al. Reducedtreatmentintensity in patientswithearly-stageHodgkin'slymphoma. N Engl J Med. 2010;363(7):640-52.

  21. Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-fieldradiotherapy in early-stageHodgkinlymphoma: matureresults of the G4 trial. Ann Oncol. 2013;24(4):1044-8.

  22. Eich HT, Diehl V, Görgen H, et al. Intensifiedchemotherapy and dose-reducedinvolved-fieldradiotherapy in patientswithearlyunfavorableHodgkin'slymphoma: final analysis of the German HodgkinStudyGroup HD11 trial. J ClinOncol. 2010;28(27):4199-206.

  23. Von tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in earlyunfavorableHodgkin'slymphoma: final analysis of the German HodgkinStudyGroup HD14 trial. J ClinOncol. 2012;30(9):907-13.Radford 2015

  24. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directedtherapyforearly-stageHodgkin'slymphoma. N Engl J Med. 2015;372(17):1598-607.

  25. André MPE, Girinsky T, Federico M, et al. EarlyPositronEmissionTomography Response-AdaptedTreatment in Stage I and II HodgkinLymphoma: Final Results of theRandomized EORTC/LYSA/FIL H10 Trial. J ClinOncol. 2017;35(16):1786-1794.

  26. Johnson P, Federico M, Kirkwood A, et al. AdaptedTreatmentGuidedbyInterim PET-CT Scan in AdvancedHodgkin'sLymphoma. N Engl J Med. 2016;374(25):2419-29.

  27. Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidationradiotherapy in patientswithadvancedHodgkin'slymphoma: survival data fromthe UKLG LY09 randomizedcontrolled trial (ISRCTN97144519). J ClinOncol. 2010;28(20):3352-9.

  28. Gallamini A, Tarella C, Viviani S, et al. EarlyChemotherapyIntensificationWithEscalated BEACOPP in PatientsWithAdvanced-StageHodgkinLymphomaWith a Positive InterimPositronEmissionTomography/ComputedTomographyScanAfterTwo ABVD Cycles: Long-TermResults of the GITIL/FIL HD 0607 Trial. J ClinOncol. 2018;36(5):454-462.

  29. Gordon LI, Hong F, Fisher RI, et al. Randomizedphase III trial of ABVD versus Stanford V withorwithoutradiationtherapy in locallyextensive and advanced-stageHodgkinlymphoma: anintergroupstudycoordinatedbythe Eastern CooperativeOncologyGroup (E2496). J ClinOncol. 2013;31(6):684-91.

  30. Borchmann P, Haverkamp H, Diehl V, et al. Eightcycles of escalated-dose BEACOPP comparedwithfourcycles of escalated-dose BEACOPP followedbyfourcycles of baseline-dose BEACOPP withorwithoutradiotherapy in patientswithadvanced-stagehodgkin'slymphoma: final analysis of the HD12 trial of the German HodgkinStudyGroup. J ClinOncol. 2011;29(32):4234-42.

  31. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensitychemotherapy and PET-guidedradiotherapy in patientswithadvancedstageHodgkin'slymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-9.

  32. Hiddemann W, Cheson BD. Howwemanagefollicularlymphoma. Leukemia. 2014;28(7):1388-95.

  33. Lowry L, Smith P, Qian W, et al. Reduceddoseradiotherapyfor local control in non-Hodgkinlymphoma: a randomisedphase III trial. RadiotherOncol. 2011;100(1):86-92.

  34. Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapyforpatientswithindolentlymphoma (FORT): a randomisedphase 3 non-inferiority trial. LancetOncol. 2014;15(4):457-63.

  35. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus threecycles of CHOP and involved-fieldradiotherapyforpatientswithlimited-stageaggressive B-celllymphoma: SouthwestOncologyGroupstudy 0014. J ClinOncol. 2008;26(14):2258-63.

  36. Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 withorwithoutradiotherapy in nonbulkylimited-stagediffuselarge B-celllymphoma. Blood. 2018;131(2):174-181

  37. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapywithorwithoutrituximab in youngpatientswithgood-prognosis diffuselarge-B-celllymphoma: 6-year results of an open-labelrandomisedstudy of theMabThera International Trial (MInT) Group. LancetOncol. 2011;12(11):1013-22.

  38. Ricardi U. ESTRO school 2016

  39. Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulkydisease in elderlypatientswithaggressive B-celllymphoma. J ClinOncol. 2014;32(11):1112-8.

  40. Pfreundschuh M,  Christofyllakis K,  Altmann B et al. Radiotherapy to bulkydisease PET-negativeafterimmunochemotherapy in elderly DLBCL patients: Results of a plannedinterimanalysis of thefirst 187 patientswithbulkydiseasetreated in the OPTIMAL>60 study of the DSHNHL. Journal of ClinicalOncology 2017 35:15_suppl, 7506-7506 

  41. Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapyonoutcome of patientswithaggressive B-celllymphoma and skeletalinvolvement. J ClinOncol. 2013;31(32):4115-22.

  42. Constine LS, Yahalom J, Ng AK, et al. The Role of RadiationTherapy in PatientsWithRelapsedorRefractoryHodgkinLymphoma: GuidelinesFromthe International LymphomaRadiationOncologyGroup. Int J RadiatOncolBiolPhys. 2018;100(5):1100-1118.

  43. Ng AK, Yahalom J, Goda JS, et al. Role of RadiationTherapy in PatientsWithRelapsed/RefractoryDiffuseLarge B-CellLymphoma: Guidelinesfromthe International LymphomaRadiationOncologyGroup. Int J RadiatOncolBiolPhys. 2018;100(3):652-669.

bottom of page